Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026

What happened

Anteris will present first 30-day clinical and blood-flow results for its medium-size DurAVR heart valve from the EMBARK study at TCT 2026 in San Diego, October 31-November 3. A second session will cover the valve's technology and a recorded case.

Confirmed

Global impact / market context

If the medium-size valve shows good 30-day results, doctors gain confidence in a product that could win share in heart-valve replacement. That supports future sales and the case for spending on manufacturing and clinical studies.

Analyst inference

Anteris is a small medtech company whose value rests on DurAVR's clinical evidence. Positive data can support investor confidence and fundraising. Disappointing results would raise doubts about the design and could delay plans to reach more patients.

Analyst inference

What to watch

1. The presentation reports 30-day clinical and blood-flow outcomes in severe aortic stenosis patients who received the medium-size DurAVR valve in the ongoing EMBARK study. Confirmed
2. Watch for complication rates, valve performance and how results compare with existing valves, because these determine whether doctors adopt the device and support future revenue. Analyst inference
3. Track the separate session on emerging heart-valve technology for the company's stated case for the biomimetic design, meaning a valve built to mimic natural tissue behavior. Proposed

Evidence

• globenewswire.com